The abstract is read at the publisher; the summary is JClub's.
Emerging phase 2/3 drugs and selected phase 1/2 cellular-therapy trials are targeting actionable molecular and cellular pathways in systemic sclerosis, with CAR T-cell therapy highlighted as a major innovation.
- Why it matters: Systemic sclerosis has the highest mortality among rheumatic diseases and markedly reduces quality of life, yet there is still no approved therapy that treats the overall disease.
- What they did: The review surveys compounds in phase 2 and phase 3 trials and discusses how new mechanistic insights are being used to test targeted strategies, alongside patient stratification and personalized approaches.
- The result: The pipeline suggests that mechanism-driven, stratified treatment designs may improve trial responsiveness and generalisability, and cellular therapies such as CAR T-cell therapy could substantially improve outcomes in systemic sclerosis.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.